Бойкот раку. Защитите себя и своих близких! Советы врача-онколога из Великобритании - страница 13

60. Yin Cao1, Jing Ma2. Body Mass Index, Prostate Cancer – Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res April 2011 4; 486.

61. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.

62. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366–81.

63. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89:385–9.

64. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.Nat Rev Cancer 2004; 4: 579–91.

65. Pasquali R, Casimirri F, Cantobelli S, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men.Metabolism 1991; 40: 101–4.

66. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004; 101: 2476–81.

67. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis.JAMA.1995; 273: 1605–1609.

68. Stolzenberg-Solomon RZ, Adams K, Leitzmann M, et al. Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health – AARP Diet and Health Cohort.Am J Epidemiol. 2008; 167(5): 586–597.

69. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large US cohort.Cancer Epidemiol Biomarkers Prev. 2005; 14(2): 459–466.

70. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies.Int J Cancer. 2007; 120(9): 1993–1998.

71. Donghui Li, PhD; Jeffrey S. Morris, PhD; Jun Liu, MS; Manal M. Hassan, MD, PhD; R. Sue Day, PhD; Melissa L. Bondy, PhD; James L. Abbruzzese, MD. Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer. JAMA. 2009; 301(24): 2553–2562.

72. S C Larsson and A Wolk. Obesity and the risk of gallbladder cancer: a meta-analysis, British Journal of Cancer (2007) 96, 1457–1461.

73. Zatonski W, La Vecchia C, Levi F, Negri E, Lucchini F. Descriptive epidemiology of gall-bladder cancer in Europe. J Cancer Res Clin Oncol 1993; 119: 165—71.

74. Zatonski WA, Lowenfels AB, Boyle P, Maisonneuve P, Bueno de Mesquita HB, Ghadirian P, Jain M, Przewozniak K, Baghurst P, Moerman CJ, Simard A, Howe GR, et al.Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 1997; 89: 1132—8.

75. Purslow LR, Sandhu MS, Forouhi N, et al.Energy Intake at Breakfast and Weight Change: Prospective Study of 6,764 Middle-aged Men and Women.Am J Epidemiol 2007; Dec 12

76. Jemal A, Bray F, Center MM et al. Global cancer statistics.CA Cancer J Clin 2011; 61: 69–90.

77. Vanni E, Bugianesi E, Kotronen A et al. From the metabolic syndrome to NAFLD or vice versa?Dig Liver Dis 2010; 42: 320–330.

78. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002; 287: 2414–2423.

79. Augustin LS, Franceschi S, Jenkins DJ et al. Glycemic index in chronic disease: a review.Eur J Clin Nutr 2002; 56: 1049–1071.

80. Saunders D, Seidel D, Allison M et al. Systematic review: the association between obesity and hepatocellular carcinoma – epidemiological evidence. Aliment pharmacol Ther 2010; 31: 1051–1063.

81. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005–1008.

82. WCRF/AICR. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR 2007.

83. Schlesinger S, Aleksandrova K, Pischon T et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort.